Header Logo

Connection

Jacob Rotmensch to Aged

Back to Details
This is a "connection" page, showing publications Jacob Rotmensch has written about Aged.
Jacob Rotmensch
Connection Strength
0.239
Aged
  1. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):30-5.
    View in: PubMed
    Score: 0.046
  2. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct; 20(7):1137-41.
    View in: PubMed
    Score: 0.034
  3. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? PLoS One. 2018; 13(4):e0195497.
    View in: PubMed
    Score: 0.014
  4. Identifying distinct nanoscopic features of native collagen fibrils towards early diagnosis of pelvic organ prolapse. Nanomedicine. 2016 Apr; 12(3):667-675.
    View in: PubMed
    Score: 0.012
  5. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):507-12.
    View in: PubMed
    Score: 0.012
  6. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):44-8.
    View in: PubMed
    Score: 0.011
  7. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):537-41.
    View in: PubMed
    Score: 0.011
  8. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.
    View in: PubMed
    Score: 0.010
  9. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 01; 29(16):2259-65.
    View in: PubMed
    Score: 0.009
  10. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol Oncol. 2011 Jun 01; 121(3):581-5.
    View in: PubMed
    Score: 0.009
  11. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Apr; 121(1):118-21.
    View in: PubMed
    Score: 0.009
  12. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011 Mar; 120(3):459-63.
    View in: PubMed
    Score: 0.009
  13. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011 Jan; 120(1):113-20.
    View in: PubMed
    Score: 0.009
  14. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010 Mar; 116(3):332-4.
    View in: PubMed
    Score: 0.008
  15. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Nov 10; 27(32):5337-42.
    View in: PubMed
    Score: 0.008
  16. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov; 115(2):215-20.
    View in: PubMed
    Score: 0.008
  17. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007 Apr; 105(1):138-44.
    View in: PubMed
    Score: 0.007
  18. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):1004-9.
    View in: PubMed
    Score: 0.005
  19. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1272-6.
    View in: PubMed
    Score: 0.005
  20. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1330-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.